Increase of Synergistic Secondary Antiviral Mutations in the Evolution of A(H1N1)pdm09 Influenza Virus Neuraminidases

Viruses. 2024 Jul 11;16(7):1109. doi: 10.3390/v16071109.

Abstract

The unexpected emergence of oseltamivir-resistant A(H1N1) viruses in 2008 was facilitated in part by the establishment of permissive secondary neuraminidase (NA) substitutions that compensated for the fitness loss due to the NA-H275Y resistance substitution. These viruses were replaced in 2009 by oseltamivir-susceptible A(H1N1)pdm09 influenza viruses. Genetic analysis and screening of A(H1N1)pdm09 viruses circulating in Germany between 2009 and 2024 were conducted to identify any potentially synergistic or resistance-associated NA substitutions. Selected viruses were then subjected to further characterization in vitro. In the NA gene of circulating A(H1N1)pdm09 viruses, two secondary substitutions, NA-V241I and NA-N369K, were identified. These substitutions demonstrated a stable lineage in phylogenetic analysis since the 2010-2011 influenza season. The data indicate a slight increase in viral NA bearing two additional potentially synergistic substitutions, NA-I223V and NA-S247N, in the 2023-2024 season, which both result in a slight reduction in susceptibility to NA inhibitors. The accumulation of secondary synergistic substitutions in the NA of A(H1N1)pdm09 viruses increases the probability of the emergence of antiviral-resistant viruses. Therefore, it is crucial to closely monitor the evolution of circulating influenza viruses and to develop additional antiviral drugs against different target proteins.

Keywords: A(H1N1)pdm09; influenza viruses; monitoring; neuraminidase inhibitor; oseltamivir; permissive mutations; resistance; secondary mutations; surveillance.

MeSH terms

  • Amino Acid Substitution
  • Animals
  • Antiviral Agents* / pharmacology
  • Dogs
  • Drug Resistance, Viral* / genetics
  • Evolution, Molecular*
  • Germany
  • Humans
  • Influenza A Virus, H1N1 Subtype* / drug effects
  • Influenza A Virus, H1N1 Subtype* / enzymology
  • Influenza A Virus, H1N1 Subtype* / genetics
  • Influenza, Human* / virology
  • Mutation*
  • Neuraminidase* / genetics
  • Oseltamivir* / pharmacology
  • Phylogeny*
  • Viral Proteins* / genetics
  • Viral Proteins* / metabolism

Substances

  • Neuraminidase
  • Antiviral Agents
  • Viral Proteins
  • Oseltamivir
  • NA protein, influenza A virus

Grants and funding

This research received no external funding.